News
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration hebdomadaire d'opérations effectuées du 2 au 6 décembre 2024
-
COMMUNIQUÉ RÉGLEMENTÉ
Disclosure of transactions in own shares from December 2 to December 6, 2024
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia
Radius Pharmaceuticals grants Theramex exclusive commercialization rights to ELADYNOS® for osteoporosis treatment in select regions, expanding global market access